FDA: Anemia Drugs Tied to Cardiovascular Problems

The FDA is recommending more conservative dosing guidelines for Erythropoiesis-Stimulating Agents, or ESAs, when the drugs are used to treat anemia in patients with chronic kidney disease. These drugs can lead to an increased risk of cardiovascular events such as stroke, thrombosis and death.

The modified recommendations will be added to the Boxed Warning and other sections of the drug packaging  insert. According to the CDC, more than 20 million people over the age of 20 have chronic kidney disease.

To learn more, click here.